JP2019511525A5 - - Google Patents

Download PDF

Info

Publication number
JP2019511525A5
JP2019511525A5 JP2018553345A JP2018553345A JP2019511525A5 JP 2019511525 A5 JP2019511525 A5 JP 2019511525A5 JP 2018553345 A JP2018553345 A JP 2018553345A JP 2018553345 A JP2018553345 A JP 2018553345A JP 2019511525 A5 JP2019511525 A5 JP 2019511525A5
Authority
JP
Japan
Prior art keywords
cancer
composition
weight ratio
less
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018553345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511525A (ja
JP7004665B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2017/050323 external-priority patent/WO2017177270A1/en
Publication of JP2019511525A publication Critical patent/JP2019511525A/ja
Publication of JP2019511525A5 publication Critical patent/JP2019511525A5/ja
Application granted granted Critical
Publication of JP7004665B2 publication Critical patent/JP7004665B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018553345A 2016-04-12 2017-04-12 癌治療用の前酵素の組成物 Active JP7004665B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662321370P 2016-04-12 2016-04-12
US62/321,370 2016-04-12
PCT/AU2017/050323 WO2017177270A1 (en) 2016-04-12 2017-04-12 Composition of proenzymes for cancer treatment

Publications (3)

Publication Number Publication Date
JP2019511525A JP2019511525A (ja) 2019-04-25
JP2019511525A5 true JP2019511525A5 (OSRAM) 2020-05-07
JP7004665B2 JP7004665B2 (ja) 2022-02-04

Family

ID=60041280

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018553345A Active JP7004665B2 (ja) 2016-04-12 2017-04-12 癌治療用の前酵素の組成物

Country Status (6)

Country Link
US (1) US20190134166A1 (OSRAM)
EP (1) EP3442564B1 (OSRAM)
JP (1) JP7004665B2 (OSRAM)
CN (1) CN109152823A (OSRAM)
AU (1) AU2017250010A1 (OSRAM)
WO (1) WO2017177270A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7479119B2 (ja) * 2015-11-12 2024-05-08 プロパンク・ピーティーワイ・リミテッド 前酵素組成物
HK1259489A1 (zh) 2015-11-12 2019-11-29 普罗潘克股份有限公司 酶原组合物
JP7058604B2 (ja) 2016-01-29 2022-04-22 プロパンク・ピーティーワイ・リミテッド 癌治療
KR20200018690A (ko) * 2017-06-22 2020-02-19 체에스엘 베링 렝나우 아게 절단된 vwf에 의한 fviii 면역원성의 조절

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514388A (en) * 1983-03-22 1985-04-30 Psaledakis Nicholas G Proteolytic enzymes in the zymogen form to treat sarcoma cells
CZ283972B6 (cs) * 1995-05-17 1998-07-15 František Mudr. Trnka Farmaceutický prostředek s modulačním účinkem na zhoubné nádory a jeho použití
RU2012120785A (ru) * 2009-10-22 2013-11-27 ПРОПАНК ПиТиУай ЛТД Фармацевтические композиции
CZ307195B6 (cs) * 2013-11-18 2018-03-14 František Trnka Farmaceutická kompozice obsahující směs proenzymů a enzymů
JP7058604B2 (ja) * 2016-01-29 2022-04-22 プロパンク・ピーティーワイ・リミテッド 癌治療

Similar Documents

Publication Publication Date Title
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
Gylfe et al. Identification of candidate oncogenes in human colorectal cancers with microsatellite instability
WO2015109180A3 (en) Compositions and methods for treatment and detection of cancers
JP2019511525A5 (OSRAM)
JP2018507249A5 (OSRAM)
FI3827838T3 (fi) Sytokiini-indusoidun sh2-proteiinin estäminen nk-soluissa
ATE538215T1 (de) Expressionsprofil von prostatakarzinom
JP2017516775A5 (OSRAM)
CY1117687T1 (el) Adcs δουοκαρμυκινης που εμφανιζουν βελτιωμενη in vivo αντινεοπλασματικη δραστικοτητα
MX391470B (es) Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
EA201790502A1 (ru) Ингибиторы гистоновых диметилаз
WO2016123591A3 (en) Compositions and methods for treatment and detection of cancers
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
EA201492004A1 (ru) Органические композиции для лечения kras-ассоциированных заболеваний
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
CL2012003680A1 (es) Compuestos derivados de (1,8) naftiridinas 2,4 diaril sustituidas inhibidores de quinasas; su procedimiento de obtencion; composicion farmaceutica; y su uso para el tratamiento y/o prevencion de cancer, tumor, tumores malignos, entre otros; kit farmaceutico.
MX2023001945A (es) Composiciones y metodos para el cribado de tumores solidos.
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
WO2013093508A3 (en) Wnt pathway inhibitors
NZ726365A (en) Combinations for treating cancers
CR20110479A (es) Combinaciones farmaceuticas que comprenden rdea 119/bay 869766 para el tratamiento de canceres especificos
EA201101651A1 (ru) Непрерывное введение интегриновых лигандов для лечения рака
RU2017134148A (ru) Комбинация тасквинимода или его фармацевтически приемлемой соли и ингибитора pd-1 и/или pd-l1 для применения в качестве лекарственного средства
MX2013002155A (es) Compuestos para el tratamiento de cancer.
WO2020115491A3 (en) Immune checkpoint inhibitor in combination with sonodynamic therapy